CTOs on the Move

Tarzana Treatment Centers Inc

www.tarzanatc.org

 
Tarzana Treatment Centers Inc is a Tarzana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Lifemark Health Group

We are a proudly Canadian healthcare company, providing diversified healthcare services across the country.

Western Health

Western Health is a Stephenville Crossing, NL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shodair Children's Hospital

Shodair Children's Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Helena, MT. To find more information about Shodair Children's Hospital, please visit www.shodair.org

OrthoFX

OrthoFX have the best materials technology in the industry, due in large part to Loc Phan, the key scientist behind developing the first ever clear aligner. We are committed to continued polymer technology innovation by hiring a team of industry experts like Loc to understand your needs and pain points, and we can`t do it without your partnership.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.